Cytokinetics, Incorporated
CYTK
Rang in Aktien
#2262
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Aktienkurs
$64.11
Marktkapitalisierung
$8.91B
Veränderung (1 Tag)
2.32%
Veränderung (1 Jahr)
8.01%
Land
US
Handel Cytokinetics, Incorporated (CYTK)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Cytokinetics, Incorporated (CYTK)
Anzahl der ausstehenden Aktien zum June 2026: 132.09M
Laut den neuesten Finanzberichten und dem Aktienkurs von Cytokinetics, Incorporated beträgt die aktuelle Anzahl der ausstehenden Aktien 132.09M. Am Ende von December 2023 hatte das Unternehmen 96.52M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Cytokinetics, Incorporated (CYTK) von 2000 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 132.09M | 17.96% |
| 2024 | 111.98M | 16.01% |
| 2023 | 96.52M | 7.46% |
| 2022 | 89.83M | 16.83% |
| 2021 | 76.89M | 19.16% |
| 2020 | 64.52M | 12.07% |
| 2019 | 57.58M | 5.80% |
| 2018 | 54.42M | 10.15% |
| 2017 | 49.40M | 23.69% |
| 2016 | 39.94M | 3.32% |
| 2015 | 38.66M | 8.27% |
| 2014 | 35.71M | 30.92% |
| 2013 | 27.28M | 50.63% |
| 2012 | 18.11M | 53.45% |
| 2011 | 11.80M | 10.34% |
| 2010 | 10.69M | 11.81% |
| 2009 | 9.57M | 16.19% |
| 2008 | 8.23M | 3.79% |
| 2007 | 7.93M | 29.96% |
| 2006 | 6.10M | 28.12% |
| 2005 | 4.76M | 44.51% |
| 2004 | 3.30M | 935.01% |
| 2003 | 318.50K | 9.70% |
| 2002 | 290.33K | 22.69% |
| 2001 | 236.64K | 47.10% |
| 2000 | 160.87K | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | 92.22% |
US
|
|
| 396.00M | 199.80% |
US
|
|
| 478.91M | 262.58% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -52.92% |
NL
|
